Anika Therapeutics, Inc. (NASDAQ:ANIK) Files An 8-K Termination of a Material Definitive Agreement

Anika Therapeutics, Inc. (NASDAQ:ANIK) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02. Termination of a Material Definitive Agreement.

Story continues below

On December 29, 2016, Anika Therapeutics S.r.l. (formerly Fidia Advanced Biopolymers S.r.l.) (“Anika S.r.l”), the wholly-owned Italian subsidiary of Anika Therapeutics, Inc. (together with Anika S.r.l., the “Company”) notified Fidia Farmaceutici S.p.A. (“Fidia”) of its intention to terminate the lease agreement between Anika S.r.l. and Fidia, originally executed on December 30, 2009, for the facility that serves as the current headquarters for Anika S.r.l. (the “Lease”) as of March 31, 2017. On October 5, 2015, Anika S.r.l. entered into a build-to-suit lease agreement with Consorzio Zona Industriale E Porto Fluviale di Padova to which Anika S.r.l. will lease a new headquarters space in Padova, Italy, into which Anika S.r.l. will move the entirety of its operations upon its certification for occupancy and which will serve as the Company’s European headquarters moving forward. No termination or other fees are payable in connection with the termination of the Lease. In addition to the Lease, Anika S.r.l. has previously entered into a Tolling Agreement with Fidia, executed on December 30, 2009, whereby Fidia manufactures certain product intermediates and finished products for Anika S.r.l.

A summary of the material terms of the Lease was included in the Company’s Current Report on Form 8-K filed on January 6, 2010, which is qualified in its entirety by reference to the full text of the Lease (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on January 6, 2010 and incorporated herein by reference) and the full text of Amendment No. 1 to Lease Agreement, Amendment No. 2 to Lease Agreement, Translation of Amendment No. 3 to Lease Agreement, and Translation of Amendment No. 4 to Lease Agreement (filed as Exhibit 10.2, Exhibit 10.3, Exhibit 10.4, and Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q filed on May 3, 2016, respectively, and incorporated herein by reference).

[Remainder of page left blank intentionally]


About Anika Therapeutics, Inc. (NASDAQ:ANIK)

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. Its therapeutic offerings consist of products in the areas, such as Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. It offers products made from HA based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Its orthobiologics products primarily consist of viscosupplementation and regenerative orthopedics products. Its viscosupplementation franchise includes ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Recent Trading Information

Anika Therapeutics, Inc. (NASDAQ:ANIK) closed its last trading session down -0.06 at 50.75 with 95,734 shares trading hands.

An ad to help with our costs